Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.5% – Here’s Why

Mainz Biomed NV (NASDAQ:MYNZ)’s share price was down 3.5% during trading on Tuesday . The company traded as low as $1.3503 and last traded at $1.39. 511,983 shares were traded during mid-day trading, an increase of 38% from the average session volume of 371,589 shares. The stock had previously closed at $1.44.

Mainz Biomed Stock Down 3.5%

The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.43 and a current ratio of 0.52. The company has a market capitalization of $12.59 million, a PE ratio of -0.02 and a beta of 0.31. The firm’s 50-day simple moving average is $1.53 and its 200 day simple moving average is $1.21.

Institutional Trading of Mainz Biomed

A number of institutional investors have recently added to or reduced their stakes in MYNZ. Armistice Capital LLC grew its position in Mainz Biomed by 45.0% during the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock worth $402,000 after buying an additional 88,400 shares during the period. Cerity Partners LLC acquired a new stake in shares of Mainz Biomed during the 4th quarter valued at approximately $183,000. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Mainz Biomed by 200.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock valued at $34,000 after acquiring an additional 20,000 shares during the period.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.